Azzad Asset Management Inc. ADV Sells 5,402 Shares of Johnson & Johnson $JNJ

Azzad Asset Management Inc. ADV decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 13.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 35,456 shares of the company’s stock after selling 5,402 shares during the quarter. Johnson & Johnson accounts for approximately 0.6% of Azzad Asset Management Inc. ADV’s investment portfolio, making the stock its 21st largest position. Azzad Asset Management Inc. ADV’s holdings in Johnson & Johnson were worth $6,574,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. First Dallas Securities Inc. raised its position in shares of Johnson & Johnson by 4.0% in the 3rd quarter. First Dallas Securities Inc. now owns 10,996 shares of the company’s stock valued at $2,039,000 after buying an additional 423 shares in the last quarter. Smartleaf Asset Management LLC increased its stake in Johnson & Johnson by 22.1% in the third quarter. Smartleaf Asset Management LLC now owns 46,054 shares of the company’s stock valued at $8,364,000 after acquiring an additional 8,339 shares during the last quarter. First National Bank of Hutchinson raised its position in Johnson & Johnson by 187.5% during the third quarter. First National Bank of Hutchinson now owns 6,049 shares of the company’s stock valued at $1,122,000 after purchasing an additional 3,945 shares in the last quarter. a16z Perennial Management L.P. acquired a new position in Johnson & Johnson during the third quarter valued at approximately $663,000. Finally, Canada Post Corp Registered Pension Plan lifted its stake in Johnson & Johnson by 176.5% during the third quarter. Canada Post Corp Registered Pension Plan now owns 200,812 shares of the company’s stock worth $36,471,000 after purchasing an additional 128,189 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ reached new all‑time highs and technical indicators show strong buy interest, supporting momentum buyers and ETF inflows. Johnson & Johnson Is a Resilient Blue‑Chip Stock and It Just Hit New All‑Time Highs
• Positive Sentiment: RBC raised its price target to $255 and reiterated an Outperform, saying JNJ is positioned to manage legal overhang — a catalyst for investors focused on downside risk. RBC Sees Johnson & Johnson (JNJ) Well Positioned to Manage Legal Overhang
• Positive Sentiment: Regulatory approvals deepening JNJ’s oncology and medtech footprint bolster longer‑term growth expectations for the pipeline and portfolio. Johnson & Johnson Deepens Oncology And MedTech Footprint With New Approvals
• Positive Sentiment: Recent analyst upgrades drove short‑term buying (reports note JNJ trading up on upgrades), helping push the share price higher. Johnson & Johnson (NYSE:JNJ) Trading Up 1% on Analyst Upgrade
• Neutral Sentiment: Zacks and other market commentaries note elevated investor attention — useful context but not a direct catalyst beyond increasing volatility and flows. Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Analyst commentary (Globe & Mail) provides sector context and mixed views — some analysts remain bullish while others flag valuation concerns, creating a split consensus. Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Johnson & Johnson (JNJ)
• Neutral Sentiment: Commentary questioning whether current pricing fully reflects JNJ’s refocused healthcare portfolio is worth watching for longer‑term positioning but isn’t an immediate sell signal. Is Johnson & Johnson (JNJ) Pricing Reflect Recent Healthcare Portfolio Focus?

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on JNJ. Leerink Partners lifted their price target on Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a research note on Thursday, January 22nd. Freedom Capital lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 16th. Wells Fargo & Company boosted their target price on Johnson & Johnson from $230.00 to $240.00 and gave the stock an “overweight” rating in a research note on Thursday, January 22nd. Daiwa Securities Group raised their price target on shares of Johnson & Johnson from $203.00 to $237.00 and gave the company an “outperform” rating in a research note on Thursday, January 29th. Finally, UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $233.73.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $240.30 on Friday. The stock’s 50-day moving average is $213.54 and its 200-day moving average is $194.04. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $240.94. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock has a market cap of $578.95 billion, a P/E ratio of 21.75, a price-to-earnings-growth ratio of 2.33 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, hitting the consensus estimate of $2.46. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. The business had revenue of $24.56 billion for the quarter, compared to the consensus estimate of $24.14 billion. During the same period last year, the company earned $2.04 EPS. The firm’s revenue was up 9.1% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. Johnson & Johnson’s payout ratio is currently 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.